The National Pharmaceutical Pricing Authority (NPPA) has extended the price cap on knee implants by one year to September, 2021 after much deliberation.
A few weeks back, the pricing regulator had extended the price cap by a month after the earlier order validity ended in August. It was deliberating on whether to remove the price cap on orthopaedic implants like knee, claimed sources.
The price cap was valid till August 15.
The NPPA had allowed firms to take a 10 per cent hike for their knee implant products last year. The regulator had slashed prices of knee implants by almost 70 per cent around 2017 using the extraordinary powers granted under the Drug Price Control Order (DPCO), 2013.
Knee implants are devices used to replace parts of damaged knee joints in patients. In 2017, NPPA had capped the prices of cobalt chromium total knee implants at Rs 54,720.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.